A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
Status:
Completed
Trial end date:
2021-02-22
Target enrollment:
Participant gender:
Summary
This is a randomized, prospective, multicenter, open label clinical trial of convalescent
plasma compared to best supportive care for treatment of patients with severe COVID-19.
The aim of the study is to explore the therapeutic effect of convalescent plasma transfusions
on the survival and course of disease of patients with severe COVID-19. Convalescent plasma
will be collected from recovered COVID-19 patients.
Patients with severe COVID-19 will be randomly assigned to two groups. Patients in the
treatment group will receive covalescent plasma (250 - 325 ml) on days 1, 3 and 5. Patients
in the control group will receive best supportive care. Clinical condition in all patients
will be evaluated on day 14. In case of progressive COVID-19 on day 14 compared to baseline,
patients in the control group may be switched to treatment with convalescent plasma on days
15, 17 and 19.
Fifty-three patients will be included in each group. Data of each patient will be collected
until discharge but nor longer than day 60.